MINNEAPOLIS, May 01, 2018 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC Markets:PETV), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company. The updated report provides a comprehensive overview of the Company and its industry, along with a company valuation relative to its peer group. The sponsored research report also carries a rating and a price target and can be accessed at www.MarbleArchUSA.com or www.petvivo.com
In the report released today, Marble Arch Research notes that, “Slated for full-scale commercialization in May, the PetVivo platform directly improves activity, reduces pain, and is characterized by a strong safety profile. Given the efficacy of its treatment, affordable cost, and the emergence of new, profitable revenue streams for veterinarians PetVivo offers a compelling, therapy for beloved pets, vets, and owners alike. Thus, PetVivo’s new leadership team has set the stage for hockey-stick type revenue growth ahead.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTC Markets:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company's product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company's products, production processes and biomaterials. PetVivo's lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
PetVivo Holdings, Inc.
Direct: (763) 443-7272